A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)
Status:
Terminated
Trial end date:
2013-10-28
Target enrollment:
Participant gender:
Summary
This is a Phase III, randomized, double-blind, placebo-controlled, multicentre,
parallel-group study designed to evaluate the efficacy and safety of ocrelizumab added to SOC
(corticosteroid plus one of two immunosuppressant regimens) compared with placebo added to
SOC in patients with WHO or ISN Class III or IV lupus nephritis.